HXBMHelix BioMedix, Inc.

About Helix BioMedix, Inc. (HXBM)

Helix BioMedix, Inc. (HXBM) is a Biotechnology company headquartered in Bothell, WA, United States whose shares trade over-the-counter on the Pink tier.

Helix BioMedix is a preclinical biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. Our legacy R&D consists of an extensive proprietary library of patented bioactive peptides based on the body's innate immunity many of which the company has outlicensed to partners to commercialize. Helix BioMedix, Inc., is committed to building long term shareholder value through development of novel drugs for rare dermatological conditions with unmet needs and strategic management of our diverse peptide library.

Products and services

Helix BioMedix is a preclinical biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. Our legacy R&D consists of an extensive proprietary library of patented bioactive peptides based on the body’s innate immunity many of which the company has outlicensed to partners to commercialize. Helix BioMedix, Inc., is committed to building long term shareholder value through development of novel drugs for rare dermatological conditions with unmet needs and strategic management of our diverse peptide library.

HXBM key facts

Ticker symbol

HXBM

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

Bothell, WA, United States

Country of incorporation

US

Year of incorporation

2000

Employees

2

Estimated market cap

$1.61M (as of May 12, 2025)

Shares outstanding

224,709

Reporting standard

Alternative Reporting Standard

Audit status

Unaudited

Fiscal year end

12/31

Latest filing

Annual Report (Dec 31, 2024)

Helix BioMedix, Inc. leadership

• Robin L Carmichael — CEO, President
• Mark E. Landis — Controller

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with H